Retinol-Binding Protein 4 (RBP4)
Retinol-binding protein 4 is the carrier protein for vitamin A, released by the liver and by fat cells, that rises in obesity and insulin resistance and is one of the molecular links between excess fat and type 2 diabetes.
Plain English
Patient-Friendly Explanation
Retinol-binding protein 4 (RBP4) is the protein that carries vitamin A (retinol) through the bloodstream; it is made mainly in the liver and is also released by fat cells. That transport job is routine and essential. What made RBP4 interesting in obesity research is what happens when there is too much of it: in 2005 a landmark study showed that mice and humans with insulin resistance had higher RBP4 levels, that raising RBP4 by genetic manipulation actually caused insulin resistance, and that removing it improved insulin sensitivity. Later work showed that fat cells release RBP4 in step with how well they handle glucose, and that visceral fat - the fat packed around the organs - releases more of it than fat under the skin. In people with obesity RBP4 tends to be higher, and levels fall after weight loss and with improved fitness. RBP4 is not a test we order in clinic: it is a research measure with inconsistent laboratory assays, and the human data are messier than the mouse experiments. Its value is conceptual. It is one of the signals that explain how carrying excess fat interferes with insulin, and it is a good example of fat tissue behaving like an organ - sending messages that change how muscle and liver handle sugar. Vitamin A handling is genuinely altered in obesity as well, which matters when vitamin A tests are interpreted or supplements are advised.
Medical
Clinical Definition
Retinol-binding protein 4 (RBP4) is a 21 kDa lipocalin secreted principally by hepatocytes and adipocytes that transports retinol in a 1:1 complex with transthyretin; its secretion from adipocytes is GLUT4-dependent, so reduced glucose uptake in insulin-resistant fat cells diverts RBP4 from intracellular retention into the circulation. Yang and colleagues (Nature, 2005) demonstrated increased RBP4 in insulin-resistant mice and humans, that transgenic overexpression of RBP4 causes insulin resistance, and that the RBP4 antagonist fenretinide improves insulin sensitivity. Mechanistically RBP4 has been reported to impair insulin signalling in skeletal muscle through retinol-dependent JNK and phosphatidylinositol-3-kinase pathways and to increase hepatic phosphoenolpyruvate carboxykinase expression and gluconeogenesis; it also promotes low-grade inflammation and is expressed preferentially by visceral adipose tissue. Human evidence is heterogeneous: meta-analyses consistently show elevated circulating RBP4 in obesity, type 2 diabetes, polycystic ovary syndrome and gestational diabetes, with positive correlations to visceral fat, HOMA-IR, triglycerides and C-reactive protein, but prospective associations with incident diabetes are inconsistent and assay standardisation is poor, with ELISA platforms giving widely differing absolute values. RBP4 also sits within retinol homeostasis, and obesity is associated with altered vitamin A status, which complicates interpretation of both RBP4 and vitamin A measurements. Clinically RBP4 is not part of routine assessment and does not change management; the practical proxies for this pathway remain fasting glucose, HbA1c, fasting insulin or HOMA-IR, triglycerides and waist circumference, all of which fall with sustained weight loss, exercise and improved insulin sensitivity.
Key Insight
Why It Matters
RBP4 is not something to ask your doctor to test - the assays disagree with each other and the number would not change your treatment. It is worth knowing about because it shows how fat acts on the rest of the body: it releases proteins that make muscle and liver less responsive to insulin. The useful message is that the measures we already track - fasting glucose, insulin, triglycerides and waist - are the visible fingerprints of that pathway, and they improve as weight comes down.
Where this fits
Retinol-Binding Protein 4 (RBP4) is one of the concepts that comes up in metabolic health and weight at our clinic. If you are reading about it because of your own weight, the next practical step is a clinical assessment, see our medical weight loss programme for how the programme works, what it involves and what it costs.
Sources
Reviewed against standard medical references.
Medically reviewed by
Family Physician & Registered Acupuncturist, Accord Medical Clinic. MBBS (NUS), Graduate Diploma in Family Medicine (NUS), Graduate Diploma in Acupuncture (Singapore College of TCM).
Last reviewed: September 2026
This page is general health education, not medical advice. Whether any treatment is appropriate for you is a decision made in consultation after assessment.